Marjorie C. Argollo, Mariangela Allocca, Federica Furfaro, Laurent Peyrin-Biroulet and Silvio Danese* Pages 25 - 31 ( 7 )
Over the past decades, the advent of anti-TNF agents has dramatically changed the treatment algorithms for IBD. However, primarily and more importantly, secondary loss of response to anti-TNF agents, is often observed. Thus, new treatment options have been actively explored and some have already been incorporated in the current clinical practice. Among the class of anti-cytokine agents, the anti-IL12/IL23 monoclonal antibodies (mAbs) have been first presented, in clinical practice, by the anti-p40 mAb ustekinumab in Crohn’s disease (CD). More selective anti-IL23 agents (anti-p19) have shown efficacy and are being further developed, in contrast to agents inhibiting IL-17 downstream, which have failed in IBD clinical trials despite their clear efficacy in psoriasis.
Crohn's disease, IL-23, inflammatory bowel disease, monoclonal antibody anti-IL23, Th17 cell pathway cytokines, ulcerative colitis.
IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan, Department of Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre, IBD Centre, Humanitas Clinical and Research Centre, Rozzano, Milan